Scott Yerby - Si Bone Vice President CTO
| SIBN Stock | USD 12.56 0.27 2.20% |
President
Dr. Scott A. Yerby Ph.D., is Chief Technology Officer of the Company since January 2011. He has served as our Chief Technology Officer since January 2011. Prior to joining us, Dr. Yerby served as Vice President, Research and Development for ProMed, Inc., a medical supply company, from June 2009 to January 2011. From May 2007 to June 2009, Dr. Yerby sat on the board of several nonprofit organizations. From June 2000 to May 2007, Dr. Yerby served as Vice President of Research and Development for St. Francis Medical Technologies, Inc., a spinal manufacturing company, until its acquisition by Kyphon, Inc. From June 1997 to June 2000, Dr. Yerby served as Director of Experimental Biomechanics at the Palo Alto VA Hospital. Early in his career, Dr. Yerby held appointments as Consulting Assistant Professor at Stanford University in the Department of Mechanical Engineering, Division of Biomechanical Engineering, and the Department of Functional Restoration, Division of Orthopedic Surgery since 2011.
| Age | 56 |
| Tenure | 13 years |
| Address | 471 El Camino Real, Santa Clara, CA, United States, 95050 |
| Phone | 408 207 0700 |
| Web | https://si-bone.com |
Si Bone Management Efficiency
The company has return on total asset (ROA) of (0.1154) % which means that it has lost $0.1154 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2209) %, meaning that it created substantial loss on money invested by shareholders. Si Bone's management efficiency ratios could be used to measure how well Si Bone manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to drop to -0.24. At this time, Si Bone's Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jim Stephens | Integer Holdings Corp | 50 | |
| Aviva McPherron | Orthofix Medical | N/A | |
| Joseph Flanagan | Integer Holdings Corp | 61 | |
| Peter Shagory | CONMED | 55 | |
| Carter Houghton | Integer Holdings Corp | 55 | |
| Johonna Pelletier | CONMED | 51 | |
| Jon Serbousek | Orthofix Medical | 63 | |
| Joel Becker | Integer Holdings Corp | 53 | |
| Tom Thomas | Integer Holdings Corp | 53 | |
| Kevin Kenny | Orthofix Medical | 59 | |
| Eric Weinberg | Rxsight | 63 | |
| Joseph Hauser | Orthopediatrics Corp | 41 | |
| Payman Khales | Integer Holdings Corp | 54 | |
| David Bailey | Orthopediatrics Corp | 45 | |
| Shelley Thunen | Rxsight | 70 | |
| Todd Garner | CONMED | 55 | |
| Erick DeVinney | Axogen Inc | 48 | |
| Kimberley Elting | Orthofix Medical | 59 | |
| Filippo Caldini | Establishment Labs Holdings | 59 | |
| Daniel Gerritzen | Orthopediatrics Corp | 54 | |
| Tyler Lipschultz | Orthofix Medical | 57 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 |
Si Bone Leadership Team
Elected by the shareholders, the Si Bone's board of directors comprises two types of representatives: Si Bone inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SIBN. The board's role is to monitor Si Bone's management team and ensure that shareholders' interests are well served. Si Bone's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Si Bone's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saqib Iqbal, Director Relations | ||
| Anshul Maheshwari, Chief Officer | ||
| Aimee Einstein, Vice Culture | ||
| Daniel Cher, Senior Affairs | ||
| Carlton Reckling, Chief Medical Officer and Vice President Medical Affairs | ||
| Michael Pisetsky, General Counsel and Chief Compliance Officer | ||
| Laura MBA, CEO Director | ||
| Nikolas Kerr, Strategy Product | ||
| Scott Yerby, Vice President CTO | ||
| Jeff Bertolini, Senior Technology | ||
| Michael JD, Secretary Officer | ||
| Joseph Powers, VP Marketing | ||
| Anthony Recupero, Chief Commercial Officer |
SIBN Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Si Bone a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 397.27 M | ||||
| Shares Outstanding | 41.94 M | ||||
| Shares Owned By Insiders | 2.37 % | ||||
| Shares Owned By Institutions | 98.60 % | ||||
| Number Of Shares Shorted | 1.62 M | ||||
| Price To Book | 3.09 X |
Pair Trading with Si Bone
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Si Bone position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Si Bone will appreciate offsetting losses from the drop in the long position's value.Moving against SIBN Stock
The ability to find closely correlated positions to Si Bone could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Si Bone when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Si Bone - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Si Bone to buy it.
The correlation of Si Bone is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Si Bone moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Si Bone moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Si Bone can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Si Bone. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in SIBN Stock, please use our How to Invest in Si Bone guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Si Bone. If investors know SIBN will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Si Bone listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 3.817 | Quarterly Revenue Growth 0.186 | Return On Assets (0.12) | Return On Equity (0.22) |
The market value of Si Bone is measured differently than its book value, which is the value of SIBN that is recorded on the company's balance sheet. Investors also form their own opinion of Si Bone's value that differs from its market value or its book value, called intrinsic value, which is Si Bone's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Si Bone's market value can be influenced by many factors that don't directly affect Si Bone's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Si Bone's value and its price as these two are different measures arrived at by different means. Investors typically determine if Si Bone is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Si Bone's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.